Literature DB >> 26100010

Computational analysis of antigenic epitopes of avian influenza A (H7N9) viruses.

Mi Liu1, TingRui Song, Sha Hua, AiPing Wu, TaiJiao Jiang.   

Abstract

Influenza virus can rapidly change its antigenicity, via mutation in the hemagglutinin (HA) protein, to evade host immunity. The emergence of the novel human-infecting avian H7N9 virus in China has caused widespread concern. However, evolution of the antigenicity of this virus is not well understood. Here, we inferred the antigenic epitopes of the HA protein from all H7 viruses, based on the five well-characterized HA epitopes of the human H3N2 virus. By comparing the two major H7 phylogenetic lineages, i.e., the Eurasian lineage and the North American lineage, we found that epitopes A and B are more frequently mutated in the Eurasian lineage, while epitopes B and C are more frequently mutated in the North American lineage. Furthermore, we found that the novel H7N9 virus (derived from the Eurasian lineage) isolated in China in the year 2013, contains six frequently mutated sites on epitopes that include site 135, which is located in the receptor binding domain. This indicates that the novel H7N9 virus that infects human may already have been subjected to gradual immune pressure and receptor-binding variation. Our results not only provide insights into the antigenic evolution of the H7 virus but may also help in the selection of suitable vaccine strains.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26100010     DOI: 10.1007/s11427-015-4886-4

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   6.038


  7 in total

1.  Avian Influenza A (H7N9) Virus in a Wild Land Bird in Central China, Late 2015.

Authors:  Yanfeng Yao; Tao Zhang; Wenhai Yang; Zhiyong Shao; Bin He; Xiabing Chen; Lijun Wu; Erguang Jin; Haizhou Liu; Jianjun Chen; Jie Chen
Journal:  Virol Sin       Date:  2018-03-05       Impact factor: 4.327

2.  Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine.

Authors:  Huilin Ou; Wei Yao; Nanping Wu; Frederick X C Wang; Tianhao Weng; Chengcong Han; Xiangyun Lu; Dongshan Yu; Haibo Wu; Linfang Cheng; Honglin Chen; Hangping Yao; Lanjuan Li
Journal:  Oncotarget       Date:  2016-12-06

3.  Deep Sequencing of H7N9 Influenza A Viruses from 16 Infected Patients from 2013 to 2015 in Shanghai Reveals Genetic Diversity and Antigenic Drift.

Authors:  Yong-Li Xiao; Lili Ren; Xi Zhang; Jianwei Wang; Jeffery K Taubenberger; Li Qi; John C Kash; Yan Xiao; Fan Wu
Journal:  mSphere       Date:  2018-09-19       Impact factor: 4.389

4.  Development of a Colloidal Gold-Based Immunochromatographic Strip for Rapid Detection of H7N9 Influenza Viruses.

Authors:  Zhihao Sun; Baolan Shi; Feifei Meng; Ruonan Ma; Qingyun Hu; Tao Qin; Sujuan Chen; Daxin Peng; Xiufan Liu
Journal:  Front Microbiol       Date:  2018-08-31       Impact factor: 5.640

5.  Development of a Colloidal Gold-Based Immunochromatographic Strip for Rapid Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.

Authors:  Ge Li; Aiping Wang; Yumei Chen; Yaning Sun; Yongkun Du; Xun Wang; Peiyang Ding; Rui Jia; Yanwei Wang; Gaiping Zhang
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

6.  The S128N mutation combined with an additional potential N-linked glycosylation site at residue 133 in hemagglutinin affects the antigenicity of the human H7N9 virus.

Authors:  Wanli Liu; Tian Bai; Jinlei Guo; Xinlan Li; Lei Yang; Xiaojun Wang; Junfeng Guo; Xin Ma; Xiyan Li; Hongbin Liu; Jianfang Zhou; Dayan Wang; Yue-Long Shu
Journal:  Emerg Microbes Infect       Date:  2016-07-06       Impact factor: 7.163

7.  Seroprevalence of H7N9 infection among humans: A systematic review and meta-analysis.

Authors:  Qiang Wang; Ke Xu; Weihua Xie; Liuqing Yang; Haiyan Chen; Naiyang Shi; Changjun Bao; Haodi Huang; Xuefeng Zhang; Yilan Liao; Hui Jin
Journal:  Influenza Other Respir Viruses       Date:  2020-03-10       Impact factor: 4.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.